Analgesic regimen

Patent 6339105 Issued on January 15, 2002. Estimated Expiration Date:

October 12, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

3652589

Inventors

Assignee

Ortho-McNeil Pharmaceutical, Inc.

Application

No. 415753 filed on 10/12/1999

US Classes:

514/646Benzene ring containing

Examiners

Primary: Rose, Shep K.

Attorney, Agent or Firm

Palo; Ralph R.

International Class

A61K 031/135

Abstract

A regimen for the administration of tramadol for the treatment of analgesia is described. The regimen involves a slower initial titration rate of tramadol which results in a significantly lower percentage of discontinuations of therapy due to a lower incidence and severity of side effects.

Other References

Merck Index (Twelfth Edition) entry 9701 Tramadul (Ultram, Tramur) cites Flick et al U.S. Patent 3652589(1972) analgesic, 1996.
Katz Today's Therapeutic Trends 31: 177-186 (see pp. 180 181 182 183 184 Initiating Tramadul Therapy at a Dose of 25-50 MG Daily for the Firs 2-3 days reduces incidence of nausea, 1995.
Barkin Formulary 30(9):542-543 Tramdol Alternative Dosing Regimon (To Decrease Nausea/Vomiting and Other Side Effects, Day 1-25 Mg q 4 Hrs While Awake Day 2-50Mg q 8 Hours Day 3--50 Mg q. 6 Hours While Awake-Slow Titraron, Children over 10--25 Mg Every 8 Hour